A patient has clear-cell renal carcinoma with increased recurrence risk after nephrectomy and complete resection of a solitary metastasis. There is

Question

A patient has clear-cell renal carcinoma with increased recurrence risk after nephrectomy and complete resection of a solitary metastasis. There is no residual measurable disease. Which statement reflects NICE TA830?

Accepted Answer

Offer adjuvant pembrolizumab after nephrectomy and complete metastasectomy

Answer

Use pembrolizumab only when measurable residual tumour remains after metastasectomy

Answer

Use pembrolizumab only after completing postoperative radiotherapy to the renal bed

Answer

Use surveillance because adjuvant treatment excludes patients who underwent metastasectomy

Answer

Exclude pembrolizumab because metastasectomy defines incurable stage IV disease

Partial Nephrectomy — SCE Medical Oncology MCQ

A patient has clear-cell renal carcinoma with increased recurrence risk after nephrectomy and complete resection of a solitary metastasis. There is no residual measurable disease. Which statement reflects NICE TA830?